SCHEMBL24625474

SCHEMBL24625474

COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccsc2C(N)=O)n1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 12/20 0.78
▸ INSR P06213 11/20 0.78
▸ IGF1R P08069 11/20 0.78
▸ PLK1 P53350 5/20 0.71
▸ EGFR P00533 5/20 0.69
▸ MET P08581 2/20 0.68
▸ CHEK1 O14757 1/20 0.68
▸ AURKA O14965 1/20 0.68
▸ NUAK1 O60285 1/20 0.68
▸ JAK2 O60674 1/20 0.68
▸ STK10 O94804 1/20 0.68
▸ PRKD3 O94806 1/20 0.68
▸ SLC34A2 O95436 1/20 0.68
▸ CHEK2 O96017 1/20 0.68
▸ ABL1 P00519 1/20 0.68
▸ CD74 P04233 1/20 0.68
▸ ERBB2 P04626 1/20 0.68
▸ LCK P06239 1/20 0.68
▸ FYN P06241 1/20 0.68
▸ FES P07332 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27057252 0.93 PLK1 (0.68) ALKINSRIGF1RPLK1EGFR
SCHEMBL27038986 0.92 ALK (0.67) ALKINSRIGF1RPLK1EGFR
SCHEMBL30757880 0.92 ALK (0.67) ALKINSRIGF1RPLK1EGFR
SCHEMBL30757906 0.90 ALK (0.64) ALKINSRIGF1RPLK1EGFR
SCHEMBL27038969 0.90 ALK (0.64) ALKINSRIGF1RPLK1EGFR
SCHEMBL27038951 0.89 PLK1 (0.66) ALKINSRIGF1RPLK1
SCHEMBL27039168 0.86 PLK1 (0.64) ALKINSRIGF1RPLK1EGFR
SCHEMBL27039099 0.86 ALK (0.59) ALKINSRIGF1RPLK1FGFR1
SCHEMBL11916527 0.86 ALK (0.77) ALKINSRIGF1RPLK1EGFR
SCHEMBL30757893 0.86 PLK1 (0.64) ALKINSRIGF1RPLK1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-01-25 — — US disclosed
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF SINAI HEALTH SYSTEM (CA) 2024-01-25 — — US disclosed
WO-2022147620-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) 2022-07-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025887-A1 THIENYL AND CYCLOALKYL AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF NUAK KINASES, COMPOSITIONS AND USES THEREOF NUAK1, NUAK2, PNKP ALK 287/4885INSR 1723/4885IGF1R 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback